Researchers have found that medications containing trizepatide can help individuals lose weight and reduce their waist circumference, regardless of how long they have struggled with obesity. The study, which will be presented at the European Congress on Obesity, suggests that these medications, such as Mounjaro and Zepbound, can be effective for long-term weight management. The research has not yet been peer-reviewed, but the FDA has approved these medications for weight management in adults with a BMI over 30 or over 27 with weight-related comorbidities.
The study utilized data from the SURMOUNT phase 3 trials, comparing tirzepatide medications to a placebo in various groups of participants, including those with obesity and comorbidities, type 2 diabetes, and those without diabetes following lifestyle interventions or tirzepatide treatment. Participants were also categorized based on the duration of their weight issues, with results showing significant weight loss across all groups, regardless of disease duration. Reductions in waist circumference were also observed in line with weight loss percentages.
Dr. Mir Ali, a bariatric surgeon, notes that the results are not surprising given the mechanism of these medications in working with hormones to aid weight loss. However, individuals need to remain on these medications long-term for them to be effective. Discontinuing the medication can result in weight regain unless dietary and lifestyle habits are also addressed during treatment. Some mild side effects like nausea, vomiting, and constipation may occur, but starting on a low dose can help manage them.
A study in 2023 revealed that individuals who switched to a placebo after 36 weeks of medication regained weight, highlighting the need for continued treatment to maintain weight loss. Dr. Holly Lofton from NYU Langone Health emphasizes that regardless of initial BMI or the duration of obesity, patients can benefit from these medications. While the research was funded by Eli Lilly and Company, the manufacturer of Mounjaro and Zepbound, both Ali and Lofton believe that the results can be trusted, as the studies undergo FDA and peer review processes.
Overall, the findings suggest that medications containing trizepatide can be an effective non-surgical option for individuals struggling with obesity. However, long-term use and lifestyle changes are essential to sustaining weight loss. The study provides valuable insights for healthcare providers in tailoring treatment plans for patients with obesity, emphasizing that it is never too late to address weight management. Lofton stresses the importance of using clinical judgment to determine the best approach for each patient, acknowledging that individual differences should be considered in treatment decisions.
